Agios Pharmaceuticals (AGIO) vs. Its Rivals Critical Analysis

Agios Pharmaceuticals (NASDAQ: AGIO) is one of 287 publicly-traded companies in the “Bio Therapeutic Drugs” industry, but how does it contrast to its peers? We will compare Agios Pharmaceuticals to similar companies based on the strength of its risk, analyst recommendations, institutional ownership, profitability, earnings, dividends and valuation.

Profitability

This table compares Agios Pharmaceuticals and its peers’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Agios Pharmaceuticals -506.39% -69.64% -43.12%
Agios Pharmaceuticals Competitors -5,420.72% -162.12% -36.08%

Risk and Volatility

Agios Pharmaceuticals has a beta of 1.83, meaning that its share price is 83% more volatile than the S&P 500. Comparatively, Agios Pharmaceuticals’ peers have a beta of 2.37, meaning that their average share price is 137% more volatile than the S&P 500.

Institutional & Insider Ownership

93.8% of Agios Pharmaceuticals shares are held by institutional investors. Comparatively, 49.8% of shares of all “Bio Therapeutic Drugs” companies are held by institutional investors. 5.4% of Agios Pharmaceuticals shares are held by company insiders. Comparatively, 16.8% of shares of all “Bio Therapeutic Drugs” companies are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Earnings and Valuation

This table compares Agios Pharmaceuticals and its peers revenue, earnings per share and valuation.

Gross Revenue Net Income Price/Earnings Ratio
Agios Pharmaceuticals $69.89 million -$198.47 million -9.78
Agios Pharmaceuticals Competitors $290.27 million $35.99 million 57.09

Agios Pharmaceuticals’ peers have higher revenue and earnings than Agios Pharmaceuticals. Agios Pharmaceuticals is trading at a lower price-to-earnings ratio than its peers, indicating that it is currently more affordable than other companies in its industry.

Analyst Ratings

This is a summary of recent ratings and target prices for Agios Pharmaceuticals and its peers, as reported by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Agios Pharmaceuticals 0 1 11 0 2.92
Agios Pharmaceuticals Competitors 925 3358 11869 239 2.70

Agios Pharmaceuticals presently has a consensus target price of $75.70, indicating a potential upside of 23.51%. As a group, “Bio Therapeutic Drugs” companies have a potential upside of 42.67%. Given Agios Pharmaceuticals’ peers higher probable upside, analysts clearly believe Agios Pharmaceuticals has less favorable growth aspects than its peers.

Summary

Agios Pharmaceuticals peers beat Agios Pharmaceuticals on 8 of the 13 factors compared.

About Agios Pharmaceuticals

Agios Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company’s therapeutic areas of focus are cancer and rare genetic metabolic disorders, which are a group of over 600 rare genetic diseases caused by mutations, or defects, of single metabolic genes. The Company’s cancer product candidates are enasidenib and ivosidenib (AG-120), which target mutated isocitrate dehydrogenase 2 (IDH2) and isocitrate dehydrogenase 1 (IDH1), respectively, and AG-881, which targets both mutated IDH1 and mutated IDH2. These mutations are found in a range of hematological malignancies and solid tumors. The lead product candidate in its rare genetic metabolic disorder (RGD), programs, AG-348, targets pyruvate kinase-R for the treatment of pyruvate kinase deficiency. Pyruvate kinase deficiency is a rare disorder that often results in severe hemolytic anemia due to inherited mutations in the pyruvate kinase enzyme within red blood cells.

Receive News & Ratings for Agios Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agios Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit